JC
CPRX

JBF Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

JBF Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-508,600
Closed -$1.92M – 97
2018
Q3 		$1.92M Hold
508,600
– – 0.28% 21
2018
Q2 		$1.59M Buy
508,600
+50,000
+11% +$152K 0.24% 29
2018
Q1 		$1.1M Buy
+458,600
New +$1.52M 0.17% 34

Other funds holding CPRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JBF Capital's CPRX Position: Q4 2018 in Review

JBF Capital sold out of Catalyst Pharmaceutical (CPRX) in Q4 2018, closing a stake of 508,600 shares — an estimated $1.92M sold.

JBF Capital first reported a position in CPRX in Q1 2018 and held it in 3 quarters. The position peaked at $1.92M in Q3 2018. 86 funds tracked by Wall St. Rank hold CPRX as of Q4 2018.

  • JBF Capital reported no remaining Catalyst Pharmaceutical position as of Q4 2018 after selling out during the quarter.
  • JBF Capital sold 508,600 Catalyst Pharmaceutical shares in Q4 2018, an estimated $1.92M.
  • JBF Capital first reported a position in Catalyst Pharmaceutical in Q1 2018 and held it in 3 quarters.
  • JBF Capital's Catalyst Pharmaceutical position peaked at $1.92M in Q3 2018.
  • 86 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2018.

Based on JBF Capital's 13F filing for Q4 2018, filed 12 Feb 2019.